The Pathogenic Role of Ganglioside Metabolism in Alzheimer's Disease-Cholinergic Neuron-Specific Gangliosides and Neurogenesis

Overview

Journal Mol Neurobiol

Specialties Molecular Biology
Neurology

Date 2016 Jan 11

PMID 26748510

Citations 19

Authors

Toshio Ariga

Affiliations

Soon will be listed here.

Abstract

Alzheimer's disease (AD) is the most common type of dementia with clinical symptoms that include deficits in memory, judgment, thinking, and behavior. Gangliosides are present on the outer surface of plasma membranes and are especially abundant in the nervous tissues of vertebrates. Ganglioside metabolism, especially the cholinergic neuron-specific gangliosides, GQ1bα and GT1aα, is altered in mouse model of AD and patients with AD. Thus, alterations in ganglioside metabolism may participate in several events related to the pathogenesis of AD. Increased expressions of GT1aα may reflect cholinergic neurogenesis. Most changes in ganglioside metabolism occur in the specific brain areas and their lipid rafts. Targeting ganglioside metabolism in lipid rafts may represent an underexploited opportunity to design novel therapeutic strategies for AD.

Citing Articles

Bio-Inspired Polymeric Solid Lipid Nanoparticles for siRNA Delivery: Cytotoxicity and Cellular Uptake In Vitro.

Jagaran K, Habib S, Singh M Polymers (Basel). 2024; 16(23).

PMID: 39684010 PMC: 11644305. DOI: 10.3390/polym16233265.

Mechanistic and Therapeutic Implications of Protein and Lipid Sialylation in Human Diseases.

Zhong X, DAntona A, Rouse J Int J Mol Sci. 2024; 25(22).

PMID: 39596031 PMC: 11594235. DOI: 10.3390/ijms252211962.

Deciphering mouse brain spatial diversity via glyco-lipidomic mapping.

Lee J, Yin D, Yun J, Kim M, Kim S, Hwang H Nat Commun. 2024; 15(1):8689.

PMID: 39375371 PMC: 11458762. DOI: 10.1038/s41467-024-53032-8.

Potential roles of gangliosides in chemical-induced neurodegenerative diseases and mental health disorders.

Itokazu Y, Terry Jr A Front Neurosci. 2024; 18:1391413.

PMID: 38711942 PMC: 11070511. DOI: 10.3389/fnins.2024.1391413.

Lipids, Gut Microbiota, and the Complex Relationship with Alzheimer's Disease: A Narrative Review.

Simao D, Vieira V, Goncalves Tosatti J, Gomes K Nutrients. 2023; 15(21).

PMID: 37960314 PMC: 10649859. DOI: 10.3390/nu15214661.

References

Yu R, Nakatani Y, Yanagisawa M . The role of glycosphingolipid metabolism in the developing brain. J Lipid Res. 2008; 50 Suppl:S440-5. PMC: 2674698. DOI: 10.1194/jlr.R800028-JLR200. View

Kuwabara S, Ogawara K, Mizobuchi K, Koga M, Mori M, Hattori T . Isolated absence of F waves and proximal axonal dysfunction in Guillain-Barré syndrome with antiganglioside antibodies. J Neurol Neurosurg Psychiatry. 2000; 68(2):191-5. PMC: 1736791. DOI: 10.1136/jnnp.68.2.191. View

Ohmi Y, Ohkawa Y, Yamauchi Y, Tajima O, Furukawa K, Furukawa K . Essential roles of gangliosides in the formation and maintenance of membrane microdomains in brain tissues. Neurochem Res. 2012; 37(6):1185-91. DOI: 10.1007/s11064-012-0764-7. View

Molander-Melin M, Blennow K, Bogdanovic N, Dellheden B, Mansson J, Fredman P . Structural membrane alterations in Alzheimer brains found to be associated with regional disease development; increased density of gangliosides GM1 and GM2 and loss of cholesterol in detergent-resistant membrane domains. J Neurochem. 2004; 92(1):171-82. DOI: 10.1111/j.1471-4159.2004.02849.x. View

Argentino C, Sacchetti M, Toni D, Savoini G, DArcangelo E, ERMINIO F . GM1 ganglioside therapy in acute ischemic stroke. Italian Acute Stroke Study--Hemodilution + Drug. Stroke. 1989; 20(9):1143-9. DOI: 10.1161/01.str.20.9.1143. View

Svennerholm L, Brane G, Karlsson I, Lekman A, Ramstrom I, Wikkelso C . Alzheimer disease - effect of continuous intracerebroventricular treatment with GM1 ganglioside and a systematic activation programme. Dement Geriatr Cogn Disord. 2002; 14(3):128-36. DOI: 10.1159/000063604. View

Angata T, Kerr S, Greaves D, Varki N, Crocker P, Varki A . Cloning and characterization of human Siglec-11. A recently evolved signaling molecule that can interact with SHP-1 and SHP-2 and is expressed by tissue macrophages, including brain microglia. J Biol Chem. 2002; 277(27):24466-74. DOI: 10.1074/jbc.M202833200. View

Flicker C, Ferris S, Kalkstein D, Serby M . A double-blind, placebo-controlled crossover study of ganglioside GM1 treatment for Alzheimer's disease. Am J Psychiatry. 1994; 151(1):126-9. DOI: 10.1176/ajp.151.1.126. View

Kalanj S, Kracun I, Rosner H, Cosovic C . Regional distribution of brain gangliosides in Alzheimer's disease. Neurol Croat. 1991; 40(4):269-81. View

10.

Ngamukote S, Yanagisawa M, Ariga T, Ando S, Yu R . Developmental changes of glycosphingolipids and expression of glycogenes in mouse brains. J Neurochem. 2007; 103(6):2327-41. DOI: 10.1111/j.1471-4159.2007.04910.x. View

11.

Dhanushkodi A, McDonald M . Intracranial V. cholerae sialidase protects against excitotoxic neurodegeneration. PLoS One. 2011; 6(12):e29285. PMC: 3240658. DOI: 10.1371/journal.pone.0029285. View

12.

Lopez-Toledano M, Faghihi M, Patel N, Wahlestedt C . Adult neurogenesis: a potential tool for early diagnosis in Alzheimer's disease?. J Alzheimers Dis. 2010; 20(2):395-408. DOI: 10.3233/JAD-2010-1388. View

13.

Augustinsson L, Blennow K, Blomstrand C, Brane G, Ekman R, Fredman P . Intracerebroventricular administration of GM1 ganglioside to presenile Alzheimer patients. Dement Geriatr Cogn Disord. 1997; 8(1):26-33. DOI: 10.1159/000106597. View

14.

Matsuoka Y, Saito M, LaFrancois J, Saito M, Gaynor K, Olm V . Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to beta-amyloid. J Neurosci. 2003; 23(1):29-33. PMC: 6742136. View

15.

Scheibel T, Buchner J . Protein aggregation as a cause for disease. Handb Exp Pharmacol. 2006; (172):199-219. DOI: 10.1007/3-540-29717-0_9. View

16.

Pitto M, Raimondo F, Zoia C, Brighina L, Ferrarese C, Masserini M . Enhanced GM1 ganglioside catabolism in cultured fibroblasts from Alzheimer patients. Neurobiol Aging. 2005; 26(6):833-8. DOI: 10.1016/j.neurobiolaging.2004.07.006. View

17.

Wang J, Cheng A, Wakade C, Yu R . Ganglioside GD3 is required for neurogenesis and long-term maintenance of neural stem cells in the postnatal mouse brain. J Neurosci. 2014; 34(41):13790-800. PMC: 4188974. DOI: 10.1523/JNEUROSCI.2275-14.2014. View

18.

Hatzifilippou E, Koutsouraki E, Costa V, Baloyannis S . Antibodies against gangliosides in patients with dementia. Am J Alzheimers Dis Other Demen. 2014; 29(8):660-6. PMC: 10852599. DOI: 10.1177/1533317514534953. View

19.

Hayashi H, Kimura N, Yamaguchi H, Hasegawa K, Yokoseki T, Shibata M . A seed for Alzheimer amyloid in the brain. J Neurosci. 2004; 24(20):4894-902. PMC: 6729458. DOI: 10.1523/JNEUROSCI.0861-04.2004. View

20.

Rushworth J, Hooper N . Lipid Rafts: Linking Alzheimer's Amyloid-β Production, Aggregation, and Toxicity at Neuronal Membranes. Int J Alzheimers Dis. 2011; 2011:603052. PMC: 3014710. DOI: 10.4061/2011/603052. View